BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33648765)

  • 1. Association between quality of life and patient-reported complications from surgery and radioiodine in early-stage thyroid cancer survivors: A matched-pair analysis.
    Chow KY; Kurumety S; Helenowski IB; Giri S; Sturgeon C
    Surgery; 2021 Aug; 170(2):462-468. PubMed ID: 33648765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
    Cheng W; Ma C; Fu H; Li J; Chen S; Wu S; Wang H
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1353-60. PubMed ID: 23436920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors.
    Goswami S; Peipert BJ; Mongelli MN; Kurumety SK; Helenowski IB; Yount SE; Sturgeon C
    Surgery; 2019 Jul; 166(1):69-74. PubMed ID: 30898373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
    Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
    Bal CS; Kumar A; Pant GS
    Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
    Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
    Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
    Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C
    J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
    Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese Data of Efficacy of Low- and High-Dose Iodine-131 for the Ablation of Thyroid Remnant.
    Ma C; Feng F; Wang S; Fu H; Wu S; Ye Z; Chen S; Wang H
    Thyroid; 2017 Jun; 27(6):832-837. PubMed ID: 28401794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
    Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
    J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake.
    Gaertner FC; Okamoto S; Shiga T; Ito YM; Uchiyama Y; Manabe O; Hattori N; Tamaki N
    Clin Nucl Med; 2015 May; 40(5):378-83. PubMed ID: 25608175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.
    Malterling RR; Andersson RE; Falkmer S; Falkmer U; Niléhn E; Järhult J
    Acta Oncol; 2010 May; 49(4):454-9. PubMed ID: 20092427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
    Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
    J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
    Bal CS; Kumar A; Pant GS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
    Logue JP; Tsang RW; Brierley JD; Simpson WJ
    Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
    Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
    Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
    Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.